Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Free Cash Flow (2021 - 2025)

Historic Free Cash Flow for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$30.4 million.

  • Amylyx Pharmaceuticals' Free Cash Flow rose 2685.62% to -$30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.5 million, marking a year-over-year decrease of 6166.39%. This contributed to the annual value of -$167.8 million for FY2024, which is 167149.28% down from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Free Cash Flow of -$30.4 million as of Q3 2025, which was up 2685.62% from -$25.3 million recorded in Q2 2025.
  • In the past 5 years, Amylyx Pharmaceuticals' Free Cash Flow registered a high of $13.2 million during Q4 2023, and its lowest value of -$66.7 million during Q2 2024.
  • Its 5-year average for Free Cash Flow is -$26.9 million, with a median of -$28.4 million in 2021.
  • Per our database at Business Quant, Amylyx Pharmaceuticals' Free Cash Flow skyrocketed by 12622.37% in 2023 and then plummeted by 706456.83% in 2025.
  • Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Free Cash Flow stood at -$28.4 million in 2021, then crashed by 76.99% to -$50.3 million in 2022, then surged by 126.22% to $13.2 million in 2023, then tumbled by 547.35% to -$59.0 million in 2024, then soared by 48.51% to -$30.4 million in 2025.
  • Its last three reported values are -$30.4 million in Q3 2025, -$25.3 million for Q2 2025, and -$39.8 million during Q1 2025.